Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer

Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates

Published:2021-04 Issue:S3 Volume:17 Page:12-26
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Poon Darren Ming‐Chun¹²,Chan Chi‐Kwok³,Chan Tim‐Wai⁴,Cheung Foon‐Yiu⁵,Ho Lap‐Yin⁶,Kwong Philip Wai‐Kay⁵,Lee Eric Ka‐Chai⁷,Leung Angus Kwong‐Chuen⁸,Leung Simon Yiu‐Lam⁹,So Hing‐Shing¹⁰,Tam Po‐Chor¹¹,Ma Wai‐Kit¹²

Affiliation:

1. Comprehensive Oncology Centre Hong Kong Sanatorium and Hospital Happy Valley Hong Kong

2. Department of Clinical Oncology The Chinese University of Hong Kong New Territories Hong Kong

3. Department of Surgery, Prince of Wales Hospital The Chinese University of Hong Kong New Territories Hong Kong

4. Department of Clinical Oncology Queen Elizabeth Hospital Kowloon Hong Kong

5. Hong Kong Integrated Oncology Centre Central Hong Kong

6. Asia Clinic Tsim Sha Tsui Kowloon Hong Kong

7. Department of Clinical Oncology Tuen Mun Hospital New Territories Hong Kong

8. AMO Oncology Centre Tsim Sha Tsui Kowloon Hong Kong

9. Central Urology Clinic Tsim Sha Tsui Kowloon Hong Kong

10. Division of Urology, Department of Surgery United Christian Hospital Kowloon Hong Kong

11. Department of Surgery, Queen Mary Hospital University of Hong Kong Hong Kong Island Hong Kong

12. Department of Surgery Princess Margaret Hospital New Territories Hong Kong

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13580

Reference85 articles.

1. Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology

2. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

3. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

4. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

5. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology;Frontiers in Oncology;2024-01-31

2. Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns;Therapeutic Advances in Medical Oncology;2024-01